![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: BLVRA |
Gene summary for BLVRA |
![]() |
Gene information | Species | Human | Gene symbol | BLVRA | Gene ID | 644 |
Gene name | biliverdin reductase A | |
Gene Alias | BLVR | |
Cytomap | 7p13 | |
Gene Type | protein-coding | GO ID | GO:0006725 | UniProtAcc | A0A140VJF4 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
644 | BLVRA | LZE2T | Human | Esophagus | ESCC | 8.10e-03 | 7.59e-01 | 0.082 |
644 | BLVRA | LZE4T | Human | Esophagus | ESCC | 1.13e-16 | 6.27e-01 | 0.0811 |
644 | BLVRA | LZE5T | Human | Esophagus | ESCC | 3.55e-05 | 5.66e-01 | 0.0514 |
644 | BLVRA | LZE7T | Human | Esophagus | ESCC | 1.45e-07 | 5.54e-01 | 0.0667 |
644 | BLVRA | LZE8T | Human | Esophagus | ESCC | 1.81e-21 | 4.39e-01 | 0.067 |
644 | BLVRA | LZE20T | Human | Esophagus | ESCC | 3.02e-09 | 2.19e-01 | 0.0662 |
644 | BLVRA | LZE22T | Human | Esophagus | ESCC | 1.10e-04 | 7.59e-01 | 0.068 |
644 | BLVRA | LZE24T | Human | Esophagus | ESCC | 1.87e-20 | 7.19e-01 | 0.0596 |
644 | BLVRA | LZE21T | Human | Esophagus | ESCC | 1.54e-04 | 1.73e-01 | 0.0655 |
644 | BLVRA | LZE6T | Human | Esophagus | ESCC | 9.41e-06 | 5.14e-01 | 0.0845 |
644 | BLVRA | P1T-E | Human | Esophagus | ESCC | 3.42e-09 | 6.80e-01 | 0.0875 |
644 | BLVRA | P2T-E | Human | Esophagus | ESCC | 1.26e-44 | 9.17e-01 | 0.1177 |
644 | BLVRA | P4T-E | Human | Esophagus | ESCC | 5.81e-29 | 7.20e-01 | 0.1323 |
644 | BLVRA | P5T-E | Human | Esophagus | ESCC | 1.98e-12 | 3.74e-01 | 0.1327 |
644 | BLVRA | P8T-E | Human | Esophagus | ESCC | 4.00e-29 | 6.37e-01 | 0.0889 |
644 | BLVRA | P9T-E | Human | Esophagus | ESCC | 2.92e-34 | 9.09e-01 | 0.1131 |
644 | BLVRA | P10T-E | Human | Esophagus | ESCC | 9.06e-18 | 3.40e-01 | 0.116 |
644 | BLVRA | P11T-E | Human | Esophagus | ESCC | 3.83e-12 | 8.03e-01 | 0.1426 |
644 | BLVRA | P12T-E | Human | Esophagus | ESCC | 5.25e-64 | 1.29e+00 | 0.1122 |
644 | BLVRA | P15T-E | Human | Esophagus | ESCC | 1.07e-36 | 8.29e-01 | 0.1149 |
Page: 1 2 3 4 5 6 7 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004670018 | Esophagus | ESCC | heterocycle catabolic process | 286/8552 | 445/18723 | 1.12e-15 | 7.47e-14 | 286 |
GO:004427019 | Esophagus | ESCC | cellular nitrogen compound catabolic process | 288/8552 | 451/18723 | 3.03e-15 | 1.79e-13 | 288 |
GO:001943918 | Esophagus | ESCC | aromatic compound catabolic process | 295/8552 | 467/18723 | 1.09e-14 | 5.98e-13 | 295 |
GO:190136118 | Esophagus | ESCC | organic cyclic compound catabolic process | 307/8552 | 495/18723 | 9.99e-14 | 4.80e-12 | 307 |
GO:00330132 | Esophagus | ESCC | tetrapyrrole metabolic process | 37/8552 | 59/18723 | 6.23e-03 | 2.29e-02 | 37 |
GO:00424401 | Esophagus | ESCC | pigment metabolic process | 50/8552 | 84/18723 | 7.34e-03 | 2.64e-02 | 50 |
GO:00421681 | Esophagus | ESCC | heme metabolic process | 27/8552 | 42/18723 | 1.16e-02 | 3.90e-02 | 27 |
GO:190136111 | Liver | Cirrhotic | organic cyclic compound catabolic process | 213/4634 | 495/18723 | 1.58e-19 | 3.67e-17 | 213 |
GO:001943911 | Liver | Cirrhotic | aromatic compound catabolic process | 202/4634 | 467/18723 | 6.93e-19 | 1.28e-16 | 202 |
GO:004427011 | Liver | Cirrhotic | cellular nitrogen compound catabolic process | 195/4634 | 451/18723 | 2.99e-18 | 4.94e-16 | 195 |
GO:004670011 | Liver | Cirrhotic | heterocycle catabolic process | 192/4634 | 445/18723 | 7.17e-18 | 1.12e-15 | 192 |
GO:0006787 | Liver | Cirrhotic | porphyrin-containing compound catabolic process | 8/4634 | 12/18723 | 2.59e-03 | 1.53e-02 | 8 |
GO:0033015 | Liver | Cirrhotic | tetrapyrrole catabolic process | 8/4634 | 12/18723 | 2.59e-03 | 1.53e-02 | 8 |
GO:0033013 | Liver | Cirrhotic | tetrapyrrole metabolic process | 24/4634 | 59/18723 | 5.06e-03 | 2.62e-02 | 24 |
GO:0042167 | Liver | Cirrhotic | heme catabolic process | 7/4634 | 11/18723 | 7.11e-03 | 3.41e-02 | 7 |
GO:0046149 | Liver | Cirrhotic | pigment catabolic process | 7/4634 | 11/18723 | 7.11e-03 | 3.41e-02 | 7 |
GO:0006778 | Liver | Cirrhotic | porphyrin-containing compound metabolic process | 20/4634 | 49/18723 | 9.60e-03 | 4.35e-02 | 20 |
GO:004427021 | Liver | HCC | cellular nitrogen compound catabolic process | 303/7958 | 451/18723 | 9.76e-27 | 3.64e-24 | 303 |
GO:004670021 | Liver | HCC | heterocycle catabolic process | 299/7958 | 445/18723 | 2.07e-26 | 7.29e-24 | 299 |
GO:190136121 | Liver | HCC | organic cyclic compound catabolic process | 325/7958 | 495/18723 | 6.52e-26 | 2.18e-23 | 325 |
Page: 1 2 3 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BLVRA | SNV | Missense_Mutation | rs377670975 | c.481C>T | p.Arg161Trp | p.R161W | P53004 | protein_coding | deleterious(0.02) | probably_damaging(0.95) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BLVRA | SNV | Missense_Mutation | rs387906596 | c.131N>T | p.Ser44Leu | p.S44L | P53004 | protein_coding | deleterious(0) | possibly_damaging(0.871) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BLVRA | SNV | Missense_Mutation | rs377670975 | c.481N>T | p.Arg161Trp | p.R161W | P53004 | protein_coding | deleterious(0.02) | probably_damaging(0.95) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
BLVRA | SNV | Missense_Mutation | rs771053277 | c.104N>T | p.Ala35Val | p.A35V | P53004 | protein_coding | tolerated(0.12) | benign(0.201) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
BLVRA | SNV | Missense_Mutation | rs387906596 | c.131C>T | p.Ser44Leu | p.S44L | P53004 | protein_coding | deleterious(0) | possibly_damaging(0.871) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
BLVRA | insertion | Frame_Shift_Ins | novel | c.414dupA | p.Glu139ArgfsTer79 | p.E139Rfs*79 | P53004 | protein_coding | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
BLVRA | SNV | Missense_Mutation | c.710N>G | p.Ser237Cys | p.S237C | P53004 | protein_coding | tolerated(0.29) | benign(0.005) | TCGA-G3-A6UC-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD | |
BLVRA | SNV | Missense_Mutation | c.385N>A | p.Leu129Met | p.L129M | P53004 | protein_coding | deleterious(0.04) | probably_damaging(0.914) | TCGA-G3-A7M5-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
BLVRA | SNV | Missense_Mutation | novel | c.706G>T | p.Gly236Trp | p.G236W | P53004 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-44-7661-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
BLVRA | SNV | Missense_Mutation | c.597N>T | p.Met199Ile | p.M199I | P53004 | protein_coding | tolerated(0.48) | benign(0.009) | TCGA-49-6743-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | cisplatin | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
644 | BLVRA | ENZYME | Ursodeoxycholic acid |
Page: 1 |